Expanding the evidence base in transplantation: The complementary roles of randomized controlled trials and outcomes research

Transplantation

Volumn 86, Issue 1, 2008, Pages 18-25

  Takemoto, Steven K ^a   Arns, Wolfgang ^b   Bunnapradist, Suphamai ^c   Garrison, Louis P ^d   Guirado, Lluis ^e   Kalo, Zoltan ^f   Oniscu, Gabriel ^g   Opelz, Gerhard ^h   Scolari, Maria Piera ⁱ   Stefoni, Sergio ⁱ   Yaqoob, Magdi ^j   Brennan, Daniel C ^k  

^a National Institute of Transplantation Los Angeles   (United States)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e FUNDACIÓ PUIGVERT   (Spain)

^f EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^g ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ U O Nefrologia Dialisi e Trapianto   (Italy)

^j ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^k WASHINGTON UNIVERSITY   (United States)

more..

Author keywords

Immunosuppression; Outcomes research; Randomized controlled trial; Registry analysis; Transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ARTICLE; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; EXTERNAL VALIDITY; GRAFT REJECTION; HUMAN; INTERVENTION STUDY; MEDICAL RESEARCH; METHODOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REGISTER; SURGICAL TECHNIQUE; TRANSPLANTATION; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; EPIDEMIOLOGY; OBSERVATION; ORGAN TRANSPLANTATION; REPRODUCIBILITY; TREATMENT OUTCOME;

BIAS (EPIDEMIOLOGY); EVIDENCE-BASED MEDICINE; HUMANS; OBSERVATION; ORGAN TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 49849090607     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31817d4df5     Document Type: Article

References (81)

1. Woodroffe R, Yao GL, Meads C, et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: A systematic review and modelling study. Health Technol Assess 2005; 9: 1.
2. Guyatt GH, Haynes RB, Jaeschke RZ, et al. Users' guides to the medical literature: XXV. Evidence-based medicine: principles for applying the users' guides to patient care. Evidence-Based Medicine Working Group. JAMA 2000; 284: 1290.
3. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408.
4. Garrison L, Neumann P, Erickson P, et al. Using real world data for coverage and payment decisions: The ISPOR Real World Data Task Force report. International Society for Pharmaeconomics and Outcomes Research, 2007.
5. McKeeM,Britton A,BlackN,etal. Methods inhealth services research. Interpreting the evidence: Choosing between randomised and non-randomised studies. BMJ 1999; 319: 312.
6. Hornberger J, Wrone E. When to base clinical policies on observational versus randomized trial data. Ann Intern Med 1997; 127(8 Pt 2): 697.
7. Padkin A, Rowan K, Black N. Using high quality clinical databases to complement the results of randomised controlled trials: The case of recombinant human activated protein C. BMJ 2001; 323: 923.
8. Van Spall HG, Toren A, Kiss A, et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: A systematic sampling review. JAMA 2007; 297: 1233.
9. Cone DC, Lewis RJ. Should this study change my practice? Acad Emerg Med 2003; 10: 417.
10. Garrison LP Jr, Towse A, Bresnahan BW. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. Health Aff (Millwood) 2007; 26: 684.
11. Grapow MT, von Wattenwyl R, Guller U, et al. Randomized controlled trials do not reflect reality: Real-world analyses are critical for treatment guidelines! J Thorac Cardiovasc Surg 2006; 132: 5.
12. Shah SS, HallM,Goodman DM,etal. Off-label drug use inhospitalized children. Arch Pediatr Adolesc Med 2007; 161: 282.
13. Rochon PA, Gurwitz JH, Sykora K, et al. Reader's guide to critical appraisal of cohort studies: 1. Role and design. BMJ 2005; 330: 895.
14. Kennedy L, Craig AM. Global registries for measuring pharmaco-economic and quality-of-life outcomes: Focus on design and data collection, analysis and interpretation. Pharmacoeconomics 2004; 22: 551.
15. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996; 312: 1215.
16. Mendelson DN, Goodman CS, Ahn R, et al. Outcomes and effectiveness research in the private sector. Health Aff (Millwood) 1998; 17: 75.
17. Stewart WF, Shah NR, Selna MJ, et al. Bridging the inferential gap: The electronic health record and clinical evidence. Health Aff (Millwood) 2007; 26: w181.
18. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178.
19. Gilmore AS, Helderman JH, Ricci JF, et al. Linking the US transplant registryto administrative claims data: Expanding the potentialoftrans-plant research. Med Care 2007; 45: 529.
20. Stirnemann PM, Takemoto SK, Schnitzler MA, et al. Agreement of immunosuppression regimens described inMedicare pharmacy claims with the Organ Procurement and Transplantation Network survey. J Am Soc Nephrol 2006; 17: 2299.
21. Motheral B, Brooks J, Clark MA, et al. A checklist for retrospective database studies - Report of the ISPOR Task Force on Retrospective Databases. Value Health 2003; 6: 90.
22. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53: 217.
23. Machnicki G, Louiza S, Schnitzler MA. Economics of transplantation: A review of the literature. Transplant Rev 2006; 20: 61.
24. Puliyanda DP, Stablein DM, Dharnidharka VR. Younger age and antibody induction increase the risk for infection in pediatric renal transplantation: A NAPRTCS report. Am J Transplant 2007; 7: 662.
25. Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3: 590.
26. Burroughs TE, Swindle J, Takemoto S, et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation 2007; 83: 1027.
27. Hardinger KL, Brennan DC, Lowell J, et al. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 2004; 17: 609.
28. Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005; 16: 496.
29. Kutinova A, Woodward RS, Ricci JF, et al. The incidence and costs of sepsis and pneumonia before and after renal transplantation in the United States. Am J Transplant 2006; 6: 129.
30. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacroli-mus Multicenter Renal Study Group. Transplantation 1997; 64: 436.
31. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977.
32. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605.
33. Lachenbruch PA, Rosenberg AS, Bonvini E, et al. Biomarkers and surrogate endpoints in renal transplantation: Present status and considerations for clinical trial design. Am J Transplant 2004; 4: 451.
34. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311.
35. KaplanB,Schold J,Meier-Kriesche HU. Poor predictive valueof serum creatinine for renal allograft loss. Am J Transplant 2003; 3: 1560.
36. Kasiske BL. Endpoint or turning point? Am J Transplant 2003; 3: 1463.
37. Placebo-controlled study of mycophenolate mofetil combined with cy-closporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345: 1321.
38. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225.
39. Meier-Kriesche HU, Ojo AO, Leichtman AB, et al. Interaction of my-cophenolate mofetil and HLA matching on renal allograft survival. Transplantation 2001; 71: 398.
40. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US preventive services task force: A review of the process. Am J Prev Med 2001; 20(3 Suppl): 21.
41. Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclos-porin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regressionofrandomised trial data.BMJ 2005; 331: 810.
42. Webster AC, Lee VW, Chapman JR, et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234.
43. Yao G, Albon E, Adi Y, et al. A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children. Health Technol Assess 2006; 10: iii.
44. Lim AK, Manley KJ, Roberts MA, et al. Fish oil treatment for kidney transplant recipients: A meta-analysis of randomized controlled trials. Transplantation 2007; 83: 831.
45. Furberg CD, Levin AA, Gross PA, et al. The FDA and drug safety: A proposal for sweeping changes. Arch Intern Med 2006; 166: 1938.
46. Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287: 2215.
47. Barton S. Which clinical studies provide the best evidence? The best RCT still trumps the best observational study. BMJ 2000; 321: 255.
48. Mamdani M, Sykora K, Li P, et al. Reader's guide to critical appraisal of cohort studies. 2. Assessing potential for confounding. BMJ 2005; 330: 960.
49. Sacks H, Chalmers TC, Smith H Jr. Randomized versus historical controls for clinical trials. Am J Med 1982; 72: 233.
50. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: What it is and what it isn't. BMJ 1996; 312: 71.
51. Petticrew M, Roberts H. Evidence, hierarchies, and typologies: Horses for courses. J Epidemiol Community Health 2003; 57: 527.
52. Kaplan B, Schold J, Meier-Kriesche HU. Overview of large database analysis in renal transplantation. Am J Transplant 2003; 3: 1052.
53. Normand SL, Sykora K, Li P, et al. Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding. BMJ 2005; 330: 1021.
54. Deeks JJ, Dinnes J, D'Amico R, et al. Evaluating non-randomised intervention studies. Health Technol Assess 2003; 7: iii.
55. Kurth T, Walker AM, Glynn RJ, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006; 163: 262.
56. Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006; 82: 102.
57. Takemoto SK, Pinsky BW, Schnitzler MA, et al. A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients. Am J Transplant 2007; 7: 2704.
58. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887.
59. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342: 1878.
60. MacLehose RR, Reeves BC, Harvey IM, et al. A systematic review of comparisons of effect sizes derived from randomised and non-randomised studies. Health Technol Assess 2000; 4: 1.
61. Tooth L, Ware R, Bain C, et al. Quality of reporting of observational longitudinal research. Am J Epidemiol 2005; 161: 280.
62. Downs SH, Black N. The feasibility of creating a checklist for the assessmentof the methodological quality bothof randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998; 52: 377.
63. Fritsche L, EineckeG,Fleiner F, etal. Reportsoflarge immunosuppres-sion trials in kidney transplantation: room for improvement. Am J Transplant 2004; 4: 738.
64. Budde K, Fritsche L. Proposal for guidelines for publication of randomized trialsinthe American JournalofTransplantation.Am J Transplant 2005; 5(4 Pt 1): 644.
65. Willems JS, Sanders CR, Riddiough MA, et al. Cost effectiveness of vaccination against pneumococcal pneumonia.N EnglJMed1980; 303: 553.
66. Riddiough MA, Sisk JE, Bell JC. Influenza vaccination. JAMA 1983; 249: 3189.
67. Eddy DM. Screening for cervical cancer. Ann Intern Med 1990; 113: 214.
68. Goldman L, Weinstein MC, Goldman PA, et al. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991; 265: 1145.
69. Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: Uses, roles, and validity. Value Health 2001; 4: 348.
70. Keown PA, Kiberd B, Balshaw R, et al. An economic model of 2-hour post-dose ciclosporin monitoring in renal transplantation. Pharmacoeconomics 2004; 22: 621.
71. McDonald JC. The national organ procurement and transplantation network. JAMA 1988; 259: 725.
72. Opelz G, Dohler B. Multicenter analysis of kidney preservation. Transplantation 2007; 83: 247.
73. Smith JM, Stablein DM, Munoz R, et al. Contributions of the transplant registry: The 2006 Annual Report of the North American Pe-diatric Renal Trials and Collaborative Studies (NAPRTCS). Pediatr Transplant 2007; 11: 366.
74. Opelz G. The benefit of exchanging donor kidneys among transplant centers. N Engl J Med 1988; 318: 1289.
75. CicciarelliJ, Terasaki PI, Mickey MR. The effect of zero HLA class I and II mismatching in cyclosporine-treated kidney transplant patients. Transplantation 1987; 43: 636.
76. Takemoto S, Terasaki PI, Cecka JM, et al. Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors. The UNOS Scientific Renal Transplant Registry. N Engl J Med 1992; 327: 834.
77. Terasaki PI, Cecka JM, Gjertson DW,et al. High survival ratesof kidney transplants from spousal and living unrelated donors. N Engl J Med 1995; 333: 333.
78. Andreoni K, Brayman K, Guidenger M, et al. Kidney and pancreas transplantation inthe United States, 1996-2005. Am J Transplant 2007; 7(s1): 1359.
79. Aydingoz SE, Takemoto SK, Pinsky BW, et al. The impact of human leukocyte antigen matching ontransplant complications and immuno-suppression dosage. Hum Immunol 2007; 68: 491.
80. McCulloch P, Taylor I, Sasako M, et al. Randomised trials in surgery: Problems and possible solutions. BMJ 2002; 324: 1448.
81. Concato J, Horwitz RI. Beyond randomised versus observational studies. Lancet 2004; 363: 1660.